Walvax Biotechnology Co., Ltd. (SHE:300142)
China · Delayed Price · Currency is CNY 12.88
+0.23 (1.82%)
Apr 8, 2026, 3:04 PM CST
Walvax Biotechnology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,413 | 2,804 | 4,106 | 5,079 | 3,452 |
Other Revenue | 5.72 | 17.86 | 7.92 | 7.65 | 10.5 |
| 2,418 | 2,821 | 4,114 | 5,086 | 3,463 | |
Revenue Growth (YoY) | -14.29% | -31.41% | -19.12% | 46.89% | 17.82% |
Cost of Revenue | 631.8 | 742.2 | 749.39 | 673.14 | 403.54 |
Gross Profit | 1,786 | 2,079 | 3,364 | 4,413 | 3,059 |
Selling, General & Admin | 1,245 | 1,399 | 1,817 | 2,302 | 1,636 |
Research & Development | 291.81 | 595.77 | 776.43 | 922.25 | 616.36 |
Other Operating Expenses | -3.46 | -4.12 | -100 | 16.48 | 19.83 |
Operating Expenses | 1,682 | 2,055 | 2,533 | 3,239 | 2,267 |
Operating Income | 104.33 | 24.01 | 831.05 | 1,174 | 792.22 |
Interest Expense | -0.91 | -8.43 | -5.95 | -7.11 | -5.77 |
Interest & Investment Income | 69.78 | 66.75 | 81.35 | 81.82 | 103.29 |
Currency Exchange Gain (Loss) | -2.63 | 4.05 | 3.06 | 0.82 | -0.22 |
Other Non Operating Income (Expenses) | 2.34 | 169.74 | -63.64 | -75.39 | 33.88 |
EBT Excluding Unusual Items | 172.91 | 256.12 | 845.86 | 1,174 | 923.4 |
Gain (Loss) on Sale of Investments | 29.68 | -98.34 | -234.75 | -199.33 | -280.74 |
Gain (Loss) on Sale of Assets | 0.08 | -1.77 | -0.83 | -0.38 | 0.23 |
Asset Writedown | -88.25 | -7.68 | -11.31 | -1.66 | -5.11 |
Other Unusual Items | 51.69 | 36.17 | - | 97.8 | 71.15 |
Pretax Income | 166.11 | 184.5 | 598.98 | 1,070 | 708.95 |
Income Tax Expense | 40.96 | 10.1 | 87.65 | 132.24 | 107.59 |
Earnings From Continuing Operations | 125.16 | 174.4 | 511.33 | 938.23 | 601.35 |
Net Income to Company | 125.16 | 174.4 | 511.33 | 938.23 | 601.35 |
Minority Interest in Earnings | 52.58 | -32.24 | -91.93 | -209.57 | -173.6 |
Net Income | 177.74 | 142.16 | 419.39 | 728.65 | 427.75 |
Net Income to Common | 177.74 | 142.16 | 419.39 | 728.65 | 427.75 |
Net Income Growth | 25.03% | -66.10% | -42.44% | 70.35% | -57.36% |
Shares Outstanding (Basic) | 1,600 | 1,599 | 1,600 | 1,603 | 1,569 |
Shares Outstanding (Diluted) | 1,600 | 1,599 | 1,600 | 1,604 | 1,573 |
Shares Change (YoY) | 0.05% | -0.06% | -0.21% | 1.93% | 0.90% |
EPS (Basic) | 0.11 | 0.09 | 0.26 | 0.45 | 0.27 |
EPS (Diluted) | 0.11 | 0.09 | 0.26 | 0.45 | 0.27 |
EPS Growth | 24.97% | -66.08% | -42.32% | 67.12% | -57.74% |
Free Cash Flow | -18.62 | 486.49 | 188.25 | 110.31 | -398.21 |
Free Cash Flow Per Share | -0.01 | 0.30 | 0.12 | 0.07 | -0.25 |
Dividend Per Share | 0.155 | 0.010 | 0.010 | 0.010 | 0.027 |
Dividend Growth | 1450.00% | - | - | -62.96% | -61.43% |
Gross Margin | 73.87% | 73.69% | 81.78% | 86.77% | 88.35% |
Operating Margin | 4.31% | 0.85% | 20.20% | 23.08% | 22.88% |
Profit Margin | 7.35% | 5.04% | 10.20% | 14.32% | 12.35% |
Free Cash Flow Margin | -0.77% | 17.24% | 4.58% | 2.17% | -11.50% |
EBITDA | 485.6 | 387.61 | 1,121 | 1,422 | 927.65 |
EBITDA Margin | 20.08% | 13.74% | 27.25% | 27.96% | 26.79% |
D&A For EBITDA | 381.28 | 363.59 | 289.97 | 248.4 | 135.43 |
EBIT | 104.33 | 24.01 | 831.05 | 1,174 | 792.22 |
EBIT Margin | 4.31% | 0.85% | 20.20% | 23.08% | 22.88% |
Effective Tax Rate | 24.65% | 5.48% | 14.63% | 12.35% | 15.18% |
Revenue as Reported | 2,418 | 2,821 | 4,114 | 5,086 | - |
Advertising Expenses | 28.28 | 42.66 | 78.01 | 94.83 | 24.15 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.